Anteris Technologies (AU:AVR) has released an update.
Anteris Technologies has received a $1.4 million refund from the Australian Government’s R&D Tax Incentive Scheme, allowing them to invest further in their pioneering heart valve technology. This funding will support the advancement of their DurAVR® THV, aimed at addressing severe aortic stenosis, as they prepare for an FDA pivotal trial. Anteris is positioned to transform the structural heart market with its innovative solutions.
For further insights into AU:AVR stock, check out TipRanks’ Stock Analysis page.
